Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $46.04 | 3 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $30.12 | 2 | $0 (2021) |
| GlaxoSmithKline, LLC. | $15.92 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15.92 | 1 | GlaxoSmithKline, LLC. ($15.92) |
| 2021 | $30.12 | 2 | Amgen Inc. ($30.12) |
All Payment Transactions
3 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: RESPIRATORY | ||||||
| 06/14/2021 | Amgen Inc. | Aimovig (Biological), Otezla, Repatha | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: Neuroscience | ||||||
| 04/21/2021 | Amgen Inc. | Aimovig (Biological), Otezla, Repatha | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 556 | 606 | $111,853 | $32,104 |
| 2022 | 11 | 648 | 675 | $130,203 | $42,372 |
| 2021 | 6 | 121 | 121 | $21,292 | $8,696 |
| 2020 | 4 | 78 | 78 | $8,019 | $3,939 |
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 90 | 95 | $30,940 | $7,765 | 25.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 62 | 62 | $20,657 | $6,087 | 29.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 70 | 72 | $16,190 | $4,275 | 26.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 52 | 52 | $11,440 | $3,684 | 32.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 24 | $9,480 | $2,855 | 30.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 19 | 19 | $7,885 | $2,846 | 36.1% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 55 | 56 | $3,275 | $1,939 | 59.2% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 11 | 12 | $1,440 | $603.36 | 41.9% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 17 | 30 | $1,500 | $486.60 | 32.4% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 24 | 24 | $1,680 | $428.89 | 25.5% |
| 73130 | X-ray of hand, minimum of 3 views | Office | 2023 | 16 | 16 | $1,232 | $362.75 | 29.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 38 | 39 | $2,326 | $357.35 | 15.4% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 12 | 12 | $457.00 | $194.40 | 42.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 16 | 16 | $940.00 | $127.53 | 13.6% |
| 81003 | Automated urinalysis test | Office | 2023 | 39 | 41 | $790.00 | $90.20 | 11.4% |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | Office | 2023 | 12 | 36 | $1,620 | $0.64 | 0.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 146 | 151 | $48,320 | $13,567 | 28.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 100 | 100 | $33,318 | $10,916 | 32.8% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 158 | 164 | $19,680 | $8,301 | 42.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 42 | 42 | $9,240 | $3,958 | 42.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 49 | 51 | $11,150 | $3,915 | 35.1% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 32 | 33 | $2,310 | $594.39 | 25.7% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 16 | 26 | $1,300 | $422.54 | 32.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 44 | 44 | $2,640 | $392.10 | 14.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 20 | 20 | $1,200 | $187.65 | 15.6% |
About Emily Wolfrum
Emily Wolfrum is a Primary Care healthcare provider based in Macomb, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2018. The National Provider Identifier (NPI) number assigned to this provider is 1871083683.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Emily Wolfrum has received a total of $46.04 in payments from pharmaceutical and medical device companies, with $15.92 received in 2024. These payments were reported across 3 transactions from 2 companies. The most common payment nature is "Food and Beverage" ($46.04).
As a Medicare-enrolled provider, Wolfrum has provided services to 1,403 Medicare beneficiaries, totaling 1,480 services with total Medicare billing of $87,111. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Practice Information
- Specialty Primary Care
- Other Specialties Family
- Location Macomb, MI
- Active Since 05/16/2018
- Last Updated 04/19/2020
- Taxonomy Code 363LP2300X
- Entity Type Individual
- NPI Number 1871083683
Products in Payments
- Aimovig (Biological) $30.12
- TRELEGY ELLIPTA (Drug) $15.92
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.